A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Lumicell, Inc.
Ipsen
Incyte Corporation
Incyte Corporation
Merck Sharp & Dohme LLC
Incyte Corporation
PharmaMar
Ipsen
Symphogen A/S
Bristol-Myers Squibb
Amphera BV
Polaris Group
Candel Therapeutics, Inc.
Xencor, Inc.
Incyte Corporation
Calithera Biosciences, Inc
AbbVie
AbbVie
Eli Lilly and Company
Shionogi Inc.
Incyte Corporation
Epizyme, Inc.
Novartis
Bayer
Incyte Corporation
Merck Sharp & Dohme LLC
Curis, Inc.
Bayer
Novartis
GlaxoSmithKline
Bayer
Novartis
Valerio Therapeutics
Valerio Therapeutics
Morphotek
AstraZeneca
Astellas Pharma Inc
Pfizer
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company